(Press-News.org) A new UC San Francisco-led study brings scientists closer to understanding the causes of a mysterious rash of cases of acute severe hepatitis that began appearing in otherwise healthy children after COVID-19 lockdowns eased in the United States and 34 other countries in the spring of 2022.
Pediatric hepatitis is rare, and doctors were alarmed when they started seeing outbreaks of severe unexplained hepatitis. There have been about 1,000 cases to date; 50 of these children needed liver transplants and at least 22 have died.
In the study, publishing on March 30 in Nature, researchers linked the disease to co-infections from multiple common viruses, in particular a strain of adeno-associated virus type 2 (AAV2). AAVs are not known to cause hepatitis on their own. They need “helper” viruses, such as adenoviruses that cause colds and flus, to replicate in the liver.
Once they returned to school, children were more susceptible to infections with these common pathogens. The study suggests that for a small subset of these children, getting more than one infection at the same time may have made them more vulnerable to severe hepatitis.
“We were surprised by the fact that the infections we detected in these children were caused not by an unusual, emerging virus, but by common childhood viral pathogens,” said Charles Chiu, MD, PhD, professor of laboratory medicine and medicine in the Division of Infectious Diseases, director of the UCSF Clinical Microbiology Laboratory, and senior author of the paper.
“That’s what led us to speculate that the timing of the outbreak was probably related to the really unusual situations we were going through with COVID-19 related school and daycare closures and social restrictions,” Chiu said. “It may have been an unintended consequence of what we have experienced during the last two-to-three years of the pandemic.”
By August 2022, clusters of cases were reported in 35 countries, including the U. S., where 358 cases were under investigation. The Centers for Disease Control and Prevention (CDC) launched an investigation into the causes.
Testing for Viruses
To conduct the study, which was backed by the CDC, researchers used polymerase chain reaction (PCR) along with various metagenomic sequencing and molecular-testing methods to examine plasma, whole blood, nasal swab and stool samples from 16 pediatric cases in six states — Alabama, California, Florida, Illinois, North Carolina and South Dakota — from Oct. 1, 2021, to May 22, 2022. The specimens were compared with 113 control samples.
In genotyping the 14 available blood samples, adeno-associated virus 2 (AAV2) was detected in 93% of the cases and human adenoviruses (HAdVs) were found in all the cases; a specific type of adenovirus linked to gastroenteritis (HAdV-41) was found in 11 cases. Additional co-infections with Epstein-Barr, herpes and enterovirus were found in 85.7% of cases.
Chiu noted the results mirrored the findings of two concurrent studies conducted in the United Kingdom, which identified the same AAV2 strain. All three studies identified co-infections from multiple viruses, and 75% of the children in the U.S. study had three or four viral infections.
Since AAVs are not considered pathogenic on their own, a direct causal link with the severe acute hepatitis has yet to be established. The study notes, however, that children may be especially vulnerable to more severe hepatitis triggered by co-infections. While infections from adeno-associated viruses can occur at any age, the peak is typically between 1 and 5 years old, and the median age of the affected children in the study was 3 years old.
The clusters of acute severe hepatitis in children have recently waned, but Chiu said the best way to protect children from this unlikely outcome is by washing hands frequently and staying home when sick.
Authors: In addition to Chiu, authors include Venice Servellita, BS/CLS, Alicia Sotomayor Gonzalez, PhD, of UCSF, and Daryl Lamson of the New York State Department of Public Health. Please see the study for additional authors.
Funding: The study was funded in part by the U.S. Centers for Disease Control and Prevention (contracts 75D30121C12641 and 75D30121C10991 C.Y.C.) and the Biomedical Advanced Research and Development Authority (BARDA) (contract 75A50122C00022), and the National Institutes of Health/National Institute of Child Health and Human Development (grant R61HD105618 C.Y.C. and C.A.R.). Additional funding was awarded under Agreement No. HSHQDC-15-C-00064 to Battelle National Biodefense Institute by the Department of Homeland Security, Science and Technology Directorate, for the management and operation of the National Biodefense Analysis and Countermeasures Center.
Disclosures: Please see the paper for a complete list of disclosures.
About UCSF: The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. UCSF Health, which serves as UCSF's primary academic medical center, includes top-ranked specialty hospitals and other clinical programs, and has affiliations throughout the Bay Area. UCSF School of Medicine also has a regional campus in Fresno. Learn more at https://ucsf.edu, or see our Fact Sheet.
###
Follow UCSF
ucsf.edu | Facebook.com/ucsf | YouTube.com/ucsf
END
Severe hepatitis outbreak linked to common childhood viruses
2023-03-30
ELSE PRESS RELEASES FROM THIS DATE:
New nanoparticles can perform gene-editing in the lungs
2023-03-30
CAMBRIDGE, MA -- Engineers at MIT and the University of Massachusetts Medical School have designed a new type of nanoparticle that can be administered to the lungs, where it can deliver messenger RNA encoding useful proteins.
With further development, these particles could offer an inhalable treatment for cystic fibrosis and other diseases of the lung, the researchers say.
“This is the first demonstration of highly efficient delivery of RNA to the lungs in mice. We are hopeful that it can be used to treat or repair ...
Racial disparities in pathological complete response among patients receiving neoadjuvant chemotherapy for early-stage breast cancer
2023-03-30
About The Study: In this study of 690 patients with early-stage breast cancer, racial disparities in response to neoadjuvant chemotherapy were associated with disparities in survival and varied across different breast cancer subtypes. This study highlights the potential benefits of better understanding the biology of primary and residual tumors.
Authors: Olufunmilayo I. Olopade, M.B.B.S., and Dezheng Huo, M.D., Ph.D., of the University of Chicago, are the corresponding authors.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2023.3329)
Editor’s ...
Racial, ethnic, education differences in age of smoking initiation among young adults
2023-03-30
About The Study: Declines in smoking prevalence and increases in the age of smoking initiation occurred more slowly for young adults with less formal education, widening existing education disparities between 2002 and 2019. Black young adults had lower smoking prevalence and older age of smoking initiation than white young adults. However, declines in smoking prevalence and increases in the age of smoking initiation occurred more slowly for this group.
Authors: Alyssa F. Harlow, Ph.D., of the University of Southern California ...
Novel immunotherapy delivery approach safe and beneficial for some melanoma patients with leptomeningeal disease
2023-03-30
HOUSTON ― A novel approach to administer intrathecal (IT) immunotherapy (directly into the spinal fluid) and intravenous (IV) immunotherapy was safe and improved survival in a subset of patients with leptomeningeal disease (LMD) from metastatic melanoma, according to interim analyses of a Phase I/Ib trial led by researchers at The University of Texas MD Anderson Cancer Center.
The study, published today in Nature Medicine, represents the first-in-human trial of concurrent IT and IV nivolumab (anti-PD-1) in melanoma patients ...
Surprise finding shows that neutrophils can be key antitumor weapons
2023-03-30
White blood cells called neutrophils have an unappreciated role in eradicating solid tumors, according to a surprise discovery from a team led by Weill Cornell Medicine scientists.
In the study, published March 30 in Cell, the researchers investigated how a T cell-based immunotherapy was able to destroy melanoma tumors even though many of the tumor cells lacked the markers or “antigens” targeted by the T cells. They found that the T cells, in attacking the tumors, activated a swarm of neutrophils—which in turn killed the tumor cells that the T cells couldn’t ...
Monitoring chronic disease burden: EHRs can help meet a serious public health challenge
2023-03-30
INDIANAPOLIS – The pandemic has highlighted the importance of increasing the flow of information on infectious diseases from electronic health records (EHRs) to public health agencies. Less attention has been paid to the value of EHR data for chronic disease surveillance.
At the HIMSS (Healthcare Information and Management Systems Society) Global Health Conference & Exhibition (HIMSS23), Brian Dixon, PhD, MPA, of Regenstrief Institute and Indiana University Richard M. Fairbanks School of Public Health and Lorna Thorpe, PhD, MPH, of NYU Grossman School of Medicine, will ...
Exploiting dark autoionizing states for enhancing the extreme ultraviolet laser power
2023-03-30
Exploiting dark autoionizing states for enhancing the extreme ultraviolet laser power
A research team unravels a new optical phenomenon involving dark autoionizing states, enhancing the power of an extreme-ultraviolet laser.
An international research team led by Professors Tsuneyuki Ozaki and François Légaré at the Institut national de la recherche scientifique (INRS), has developed a unique method to enhance the power of a laser source emitting extreme ultraviolet light pulses. The underlying mechanism of the newly observed phenomenon involves the ...
Iridium-based catalysts look set to boost efficiency of green hydrogen production
2023-03-30
Hydrogen production powered by wind and solar energy is still too expensive if it is to play a role in the clean transition via energy storage and to help decarbonize hard-to-electrify sectors. Much effort in reducing its cost focuses on enhancing production efficiency by improving the performance of iridium-based catalysts that can speed up the oxygen-related part of the electrochemical reaction involved in splitting water into its component parts, hydrogen and oxygen. A new review of the state of the field discusses its recent progress and challenges and identifies research gaps that need to be filled before such ...
A promising outlook: CAR T cells improve patient quality of life
2023-03-30
(WASHINGTON, March 30, 2023) – Chimeric antigen receptor T-cell (CAR-T) therapy has transformed cancer treatment, yet relatively few studies have investigated the impact of the therapy on longitudinal patient quality of life – an aspect of care that often suffers from receiving traditional intensive cancer medications, such as chemotherapy. A new study published in Blood Advances demonstrates that some effective cancer treatments do improve quality of life, revealing that patients with blood cancers experienced ...
E. John Wherry, PhD, recognized with the 2023 AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology
2023-03-30
PHILADELPHIA – The American Association for Cancer Research (AACR) will award E. John Wherry, PhD, with the 2023 AACR-Cancer Research Institute (CRI) Lloyd J. Old Award in Cancer Immunology during the AACR Annual Meeting 2023, April 14-19 at the Orange County Convention Center in Orlando, Florida.
Wherry is chair of the Department of Systems Pharmacology and Translational Therapeutics, director of the Institute for Immunology, and founding director of the Immune Health Project in the Perelman School of Medicine at the University of Pennsylvania. He is being honored for ...